Onasemnogene Abeparvovec Administration via Peripherally Inserted Central Catheter: A Case Report
Onasemnogene abeparvovec (OA) is the approved intravenous gene therapy for the treatment of spinal muscular atrophy (SMA). A functional copy of the human <i>SMN1</i> gene was inserted into the target motor neuron cells via a viral vector, AAV9. In clinical trials, OA was infused through...
Saved in:
Main Authors: | Inmaculada Pitarch Castellano (Author), Eduardo López Briz (Author), Eugenia Ibáñez Albert (Author), Cristina Aguado Codina (Author), Teresa Sevilla (Author), José L. Poveda Andrés (Author) |
---|---|
Format: | Book |
Published: |
MDPI AG,
2024-05-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Spinal muscular atrophy - onasemnogene abeparvovec and other therapeutic options
by: Aleksandra Alicja Majchrzak-Celińska, et al.
Published: (2020) -
Expanding the Availability of Onasemnogene Abeparvovec to Older Patients: The Evolving Treatment Landscape for Spinal Muscular Atrophy
by: Charlotte A. René, et al.
Published: (2023) -
Short-Term Safety and Efficacy of Onasemnogene Abeparvovec in 10 Patients with Spinal Muscular Atrophy: Cohort Study
by: Kristina S. Nevmerzhitskaya, et al.
Published: (2021) -
Early Development of Spinal Deformities in Children Severely Affected with Spinal Muscular Atrophy after Gene Therapy with Onasemnogene Abeparvovec-Preliminary Results
by: Venla Soini, et al.
Published: (2023) -
Interim Analysis of Treatment Outcomes of Young Children with 5q Spinal Muscular Atrophy on Gene Replacement Therapy with Onasemnogene Abeparvovec. Clinical Observations
by: Anna A. Kokorina, et al.
Published: (2023)